We are live on
!
Find out more
DM
Deerfield Management Portfolio holdings
AUM
$8.48B
1-Year Est. Return
99.04%
This Fund
S&P 500
This Quarter
Est. Return
-2.77%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$4.85B
AUM Growth
+$375M
(+8.4%)
Cap. Flow
-$1.26B
Cap. Flow
% of AUM
-25.93%
Top 10 Holdings %
Top 10 Hldgs %
37.89%
Holding
140
New
14
Increased
21
Reduced
12
Closed
14
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
IMGN
Immunogen Inc
IMGN
|
+$50.2M |
| 2 |
Gilead Sciences
GILD
|
+$48.7M |
| 3 |
Neurocrine Biosciences
NBIX
|
+$32.8M |
| 4 |
MRUS
Merus
MRUS
|
+$32.3M |
| 5 |
Glaukos
GKOS
|
+$31.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Kura Oncology
KURA
|
+$25.7M |
| 2 |
Organogenesis Holdings
ORGO
|
+$24.7M |
| 3 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
+$22.2M |
| 4 |
GoodRx Holdings
GDRX
|
+$18.9M |
| 5 |
Nuvation Bio
NUVB
|
+$18.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 51.31% |
| 2 | Financials | 1.39% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
HLVX
26
DELISTED
HilleVax
HLVX
| $28.6M | 0.59% |
+2,617,948
| New | +$31.1M |
|
27
Pharvaris
PHVS
$2.41B
| $26.3M | 0.54% |
1,190,343
-386,735
| -25% | -$7.21M |
|
|
HZNP
28
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $25M | 0.51% |
313,000
-152,000
| -33% | -$14.4M |
|
|
OMIC
29
DELISTED
Singular Genomics Systems, Inc. Common Stock
OMIC
| $24.2M | 0.5% |
211,211
-9,190
| -4% | -$1.08M |
|
30
GeneDx Holdings
WGS
$1.82B
| $23.7M | 0.49% |
571,166
+151,515
| +36% | +$10.3M |
|
|
BLU
31
DELISTED
BELLUS Health Inc.
BLU
| $22.9M | 0.47% |
2,473,000
-1,199,808
| -33% | -$9.81M |
|
|
32
Organogenesis Holdings
ORGO
$337M
| $21.7M | 0.45% |
4,447,740
-4,009,136
| -47% | -$24.7M |
|
33
Phreesia
PHR
$659M
| $21.4M | 0.44% |
+857,115
| New | +$18.9M |
|
34
Syndax Pharmaceuticals
SNDX
$2B
| $21.4M | 0.44% |
+1,111,111
| New | +$18.5M |
|
|
AMED
35
DELISTED
Amedisys
AMED
| $20.9M | 0.43% |
+199,000
| New | +$25.4M |
|
36
Tarsus Pharmaceuticals
TARS
$2.52B
| $19.3M | 0.4% |
+1,324,214
| New | +$19.9M |
|
37
Insmed
INSM
$23.6B
| $18.9M | 0.39% |
960,484
+655,912
| +215% | +$13.7M |
|
38
Revolution Medicines
RVMD
$39.2B
| $17.4M | 0.36% |
891,587
| – | – |
|
39
The Oncology Institute
TOI
$542M
| $17.1M | 0.35% |
3,383,099
+86,992
| +3% | +$634K |
|
40
Pacira BioSciences
PCRX
$1.01B
| $17M | 0.35% |
+292,000
| New | +$19.1M |
|
41
Alphatec Holdings
ATEC
$1.29B
| $15.8M | 0.33% |
2,420,547
-1,174,282
| -33% | -$10.8M |
|
42
AnaptysBio
ANAB
$1.6B
| $15.7M | 0.32% |
+772,000
| New | +$17.1M |
|
|
DALS
43
DELISTED
DA32 Life Science Tech Acquisition Corp. Class A Common Stock
DALS
| $15.5M | 0.32% |
1,600,000
| – | – |
|
|
INZY
44
DELISTED
Inozyme Pharma
INZY
| $12.9M | 0.27% |
2,696,372
+351,586
| +15% | +$1.53M |
|
|
PROF
45
Profound Medical
PROF
$249M
| $12.5M | 0.26% |
1,713,797
| – | – |
|
|
KZR
46
DELISTED
Kezar Life Sciences
KZR
| $11.7M | 0.24% |
+141,900
| New | +$12.5M |
|
47
Larimar Therapeutics
LRMR
$392M
| $11.4M | 0.24% |
5,830,249
| – | – |
|
48
TG Therapeutics
TGTX
$8.42B
| $11.4M | 0.23% |
+2,677,500
| New | +$16.7M |
|
49
Alector
ALEC
$159M
| $10.7M | 0.22% |
1,055,192
| – | – |
|
50
Foghorn Therapeutics
FHTX
$306M
| $10.6M | 0.22% |
777,525
+538,660
| +226% | +$6.95M |
|
Similar funds
FT
GRQ
PCM
VA
QC
IC
NW
AAF
Deerfield Management's Q2 2022 Portfolio in Review
As of Q2 2022, Deerfield Management held 140 positions worth $4.85B, up 8.4% from $4.47B the previous quarter. Its ten largest holdings account for 38% of the portfolio.
Deerfield Management withdrew a net $1.26B in Q2 2022, closing 14 positions and reducing 12 holdings. Its most notable exit was Mirati Therapeutics, Inc. Common Stock, an estimated $22.2M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 51% of assets, down from 54% a quarter earlier, followed by Financials.
Against the trend, Deerfield Management opened a new position in HilleVax worth $28.6M.
- Deerfield Management's largest Q2 2022 buy was HilleVax: 2,617,948 shares worth $28.6M.
- Deerfield Management added most to Immunogen Inc in Q2 2022, an estimated $50.2M increase.
- Deerfield Management's biggest Q2 2022 reduction was Kura Oncology, cutting an estimated $25.7M.
- Deerfield Management fully exited Mirati Therapeutics, Inc. Common Stock in Q2 2022, selling an estimated $22.2M.
- Deerfield Management's ten largest holdings make up 38% of its $4.85B portfolio in Q2 2022.
- Deerfield Management opened 14 new positions and closed 14 in Q2 2022.
- Deerfield Management's portfolio value rose 8.4% quarter-over-quarter to $4.85B.
Based on Deerfield Management's 13F filing for Q2 2022, filed 15 Aug 2022.